Hoffmann-La Roche
Giredestrant
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Countdown
227days
Phase 3 readout · Feb 19, 2027
What's at stake
Phase 3 trial results for Giredestrant in Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer are due Feb 19, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06065748: Phase 3 trial, sponsor Hoffmann-La Roche, drug Giredestrant. Primary completion date 2027-02-19 (estimated).”